About this trial
The goal of the proposed study is to evaluate the feasibility and initial efficacy of stabilizing lifestyle behaviors to improve glucose control and body composition in patients with pre-diabetes.
The investigator proposes that following stable lifestyle behaviors will improve patients' glucose control, body composition, and liver fat. The results from this study has the potential to impact clinical practice and patient care.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Pre-diabetic kg/m2 (hemoglobin A1c 5.7-6.9%)
25 years or older
BMI between 25-39.9 kg/m2
Sleep duration ≥6 hours a night assessed with wrist actigraphy (for 14 nights)
Disqualifiers
Chronic Kidney Disease (GFR<60)
Uncontrolled hypertension (≥160/100 mmHg)
Obstructive Sleep Apnea
Psychiatric or neurological disorder
Trial design
Parallel
Treatments tested in this trial
Fixed Schedule
BehavioralParticipants will be asked to maintain a fixed schedule for 12 weeks.
Treatment groups
Trial outcomes
Primary outcomes
Adipose Tissue Measurement - Total
Measuring total adiposity. Measured by MRI, includes both subcutaneous and visceral adipose tissue.
Adipose Tissue Measurement - Subcutaneous
Measurement of subcutaneous adiposity using MRI.
Adipose Tissue Measurement - Visceral
Measurement of visceral adiposity using MRI.
Glucose Area Under Curve
Testing glycemic control.The primary outcome variable is glucose under the curve during the oral glucose tolerance test.
Secondary outcomes
Liver Fat Content
This is to assess liver fat measured by MRS and MRI in %.
Disposition Index
This is to assess disposition index, measured using HOMA-IR. The disposition index is the product of the insulogenic index and homeostatic model of assessment for insulin resistance.
Short-term Change in Glycemia
Assessing whether short-term glycemia is changed by measuring fructosamine using two-sample t-tests.
Endothelial cell inflammation (sub-set, n≤10)
NF-κB nuclear fluorescence area for pilot study.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Columbia University
Lead sponsor
Department of Health and Human Services
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator